Pharming Group N.V. (PHARM.AS)
EUR 0.8
(-3.32%)
EUR 0.8
(-3.32%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 426.33 Million EUR | 0.13% |
| 2022 | 425.79 Million USD | 7.28% |
| 2021 | 396.9 Million EUR | -5.3% |
| 2020 | 419.11 Million EUR | 63.95% |
| 2019 | 255.63 Million EUR | 4.15% |
| 2018 | 245.44 Million EUR | 23.11% |
| 2017 | 199.37 Million EUR | 49.53% |
| 2016 | 133.33 Million EUR | 111.45% |
| 2015 | 63.05 Million EUR | -6.93% |
| 2014 | 67.75 Million EUR | 56.22% |
| 2013 | 43.37 Million EUR | 94.69% |
| 2012 | 22.27 Million EUR | -30.4% |
| 2011 | 32 Million EUR | -35.46% |
| 2010 | 49.59 Million EUR | -38.06% |
| 2009 | 80.06 Million EUR | -14.28% |
| 2008 | 93.4 Million EUR | -43.98% |
| 2007 | 166.71 Million EUR | 59.74% |
| 2006 | 104.36 Million EUR | 154.78% |
| 2005 | 40.96 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 415.92 Million EUR | -5.83% |
| 2024 Q3 | 425.51 Million USD | 2.3% |
| 2024 Q1 | 441.66 Million USD | -6.22% |
| 2023 FY | 426.33 Million EUR | 0.13% |
| 2023 Q4 | 462.85 Million USD | 6.05% |
| 2023 Q3 | 436.46 Million USD | 1.55% |
| 2023 Q2 | 429.8 Million USD | 1.61% |
| 2023 Q1 | 422.99 Million USD | -0.66% |
| 2022 Q4 | 425.79 Million USD | 11.37% |
| 2022 Q2 | 393.89 Million USD | 0.28% |
| 2022 Q3 | 382.32 Million USD | -2.94% |
| 2022 FY | 425.79 Million USD | 7.28% |
| 2022 Q1 | 392.79 Million USD | 12.05% |
| 2021 Q2 | 412.02 Million EUR | 0.85% |
| 2021 FY | 396.9 Million EUR | -5.3% |
| 2021 Q3 | 400.9 Million EUR | -2.7% |
| 2021 Q4 | 350.55 Million EUR | -12.56% |
| 2021 Q1 | 408.56 Million EUR | -2.52% |
| 2020 FY | 419.11 Million EUR | 63.95% |
| 2020 Q1 | 335.22 Million EUR | 31.13% |
| 2020 Q2 | 356.64 Million EUR | 6.39% |
| 2020 Q3 | 374.93 Million EUR | 5.13% |
| 2020 Q4 | 419.11 Million EUR | 11.78% |
| 2019 Q4 | 255.63 Million EUR | 5.81% |
| 2019 Q3 | 241.59 Million EUR | 3.25% |
| 2019 FY | 255.63 Million EUR | 4.15% |
| 2019 Q2 | 233.98 Million EUR | 4.41% |
| 2019 Q1 | 224.1 Million EUR | -8.69% |
| 2018 Q2 | 209.69 Million EUR | -0.35% |
| 2018 Q3 | 223.93 Million EUR | 6.79% |
| 2018 FY | 245.44 Million EUR | 23.11% |
| 2018 Q4 | 245.44 Million EUR | 9.61% |
| 2018 Q1 | 210.43 Million EUR | 5.54% |
| 2017 Q1 | 140.45 Million EUR | 5.34% |
| 2017 FY | 199.37 Million EUR | 49.53% |
| 2017 Q4 | 199.37 Million EUR | 21.33% |
| 2017 Q3 | 164.33 Million EUR | 13.14% |
| 2017 Q2 | 145.24 Million EUR | 3.41% |
| 2016 FY | 133.33 Million EUR | 111.45% |
| 2016 Q1 | 63.2 Million EUR | 0.24% |
| 2016 Q4 | 133.33 Million EUR | 143.27% |
| 2016 Q2 | 59.69 Million EUR | -5.56% |
| 2016 Q3 | 54.81 Million EUR | -8.18% |
| 2015 Q3 | 69.94 Million EUR | 24.32% |
| 2015 Q1 | 58.2 Million EUR | -14.09% |
| 2015 FY | 63.05 Million EUR | -6.93% |
| 2015 Q2 | 56.25 Million EUR | -3.35% |
| 2015 Q4 | 63.05 Million EUR | -9.84% |
| 2014 Q3 | 51.72 Million EUR | -7.52% |
| 2014 FY | 67.75 Million EUR | 56.22% |
| 2014 Q2 | 55.92 Million EUR | 22.47% |
| 2014 Q4 | 67.75 Million EUR | 30.99% |
| 2014 Q1 | 45.66 Million EUR | 5.29% |
| 2013 Q2 | 37.36 Million EUR | -0.71% |
| 2013 FY | 43.37 Million EUR | 94.69% |
| 2013 Q4 | 43.37 Million EUR | 35.51% |
| 2013 Q3 | 32 Million EUR | -14.35% |
| 2013 Q1 | 37.63 Million EUR | 68.94% |
| 2012 Q4 | 22.27 Million EUR | 10.86% |
| 2012 Q1 | 36.95 Million EUR | 15.45% |
| 2012 FY | 22.27 Million EUR | -30.4% |
| 2012 Q3 | 20.09 Million EUR | 0.0% |
| 2011 Q2 | 43.12 Million EUR | -7.06% |
| 2011 Q1 | 46.4 Million EUR | -6.43% |
| 2011 Q3 | 37.68 Million EUR | -12.62% |
| 2011 Q4 | 32 Million EUR | -15.07% |
| 2011 FY | 32 Million EUR | -35.46% |
| 2010 Q3 | 74.07 Million EUR | -15.7% |
| 2010 FY | 49.59 Million EUR | -38.06% |
| 2010 Q4 | 49.59 Million EUR | -33.05% |
| 2010 Q2 | 87.86 Million EUR | 6.59% |
| 2010 Q1 | 82.43 Million EUR | 2.96% |
| 2009 FY | 80.06 Million EUR | -14.28% |
| 2009 Q4 | 80.06 Million EUR | 0.0% |
| 2008 FY | 93.4 Million EUR | -43.98% |
| 2007 FY | 166.71 Million EUR | 59.74% |
| 2006 FY | 104.36 Million EUR | 154.78% |
| 2005 FY | 40.96 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -2798.298% |
| ABIVAX Société Anonyme | 327.06 Million EUR | -30.354% |
| Adocia SA | 24.95 Million EUR | -1608.365% |
| Aelis Farma SA | 26.28 Million EUR | -1522.235% |
| Biophytis S.A. | 11.93 Million EUR | -3471.88% |
| Advicenne S.A. | 12.4 Million EUR | -3336.282% |
| genOway Société anonyme | 31.84 Million EUR | -1238.907% |
| IntegraGen SA | 8 Million EUR | -5229.011% |
| Medesis Pharma S.A. | 1.92 Million EUR | -22032.161% |
| Neovacs S.A. | 47.53 Million EUR | -796.923% |
| NFL Biosciences SA | 3.97 Million EUR | -10637.333% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -2758.859% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -11278.853% |
| Sensorion SA | 46.49 Million EUR | -816.976% |
| Theranexus Société Anonyme | 7.23 Million EUR | -5790.509% |
| TME Pharma N.V. | 2.49 Million EUR | -17015.197% |
| Valbiotis SA | 33.24 Million EUR | -1182.301% |
| TheraVet SA | 7.53 Million EUR | -5558.731% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | -1108.651% |
| argenx SE | 4.11 Billion EUR | 89.632% |
| BioSenic S.A. | 9.55 Million EUR | -4360.085% |
| Celyad Oncology SA | 16.28 Million EUR | -2518.472% |
| DBV Technologies S.A. | 165.65 Million USD | -157.373% |
| Galapagos NV | 4.35 Billion EUR | 90.216% |
| Genfit S.A. | 173.87 Million EUR | -145.203% |
| GeNeuro SA | 6.31 Million EUR | -6653.466% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | -794.15% |
| Innate Pharma S.A. | 184.19 Million EUR | -131.463% |
| Inventiva S.A. | 69.13 Million EUR | -516.641% |
| MaaT Pharma SA | 42.93 Million EUR | -893.081% |
| MedinCell S.A. | 36.94 Million EUR | -1053.891% |
| Nanobiotix S.A. | 93.89 Million EUR | -354.05% |
| Onward Medical N.V. | 43.62 Million EUR | -877.193% |
| Oryzon Genomics S.A. | 106.9 Million EUR | -298.82% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | -420.561% |
| Oxurion NV | 6.55 Million EUR | -6409.001% |
| Poxel S.A. | 4.82 Million EUR | -8739.717% |
| GenSight Biologics S.A. | 9.08 Million EUR | -4591.753% |
| Transgene SA | 45.21 Million EUR | -842.875% |
| Financière de Tubize SA | 1.92 Billion EUR | 77.798% |
| UCB SA | 15.53 Billion EUR | 97.256% |
| Valneva SE | 469.39 Million EUR | 9.172% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | -1282.917% |